The Medicare GLP-1 Bridge: Who Qualifies for the $50 Copay, and What Employers Should Know

For years, Medicare Part D could not cover a GLP-1 medication when the only reason it was prescribed was weight management. Coverage existed for type 2 diabetes and, more recently, for a handful of other indications, but not for weight loss on its own. In 2026 CMS opened a temporary path around that gap, and it has direct implications for patients over 65 and for the employers who sponsor their drug coverage.

What the Medicare GLP-1 Bridge is

The Medicare GLP-1 Bridge is a short-term demonstration run by the Centers for Medicare & Medicaid Services under its Section 402 demonstration authority. It gives eligible Part D beneficiaries access to certain GLP-1 drugs between July 1, 2026 and December 31, 2027. CMS originally paired it with a planned model called BALANCE; with BALANCE not launching in 2027, CMS extended the Bridge through the end of 2027 and says it will use the data to inform Part D plans ahead of any future BALANCE implementation.

The detail that matters most for plan sponsors: the Bridge operates outside the Part D benefit’s coverage and payment flow. Part D sponsors do not carry risk for these drugs and do not have to opt in. In 2026, CMS uses a single central processor for prior authorization, claims, and pharmacy payment.

Who qualifies

Eligibility has two parts: the right kind of plan, and the right clinical picture.

Plan type

Beneficiaries must be enrolled in a standalone prescription drug plan (PDP) or a Medicare Advantage coordinated care plan with drug coverage (HMO, HMO-POS, and local or regional PPO plans). CMS lists Special Needs Plans, employer/union group waiver plans (EGWPs), and the Limited Income Newly Eligible Transition program as eligible. Some plan types, including private fee-for-service plans, are excluded. CMS’s provider FAQ has the full list.

Clinical criteria

The prescribing clinician submits a prior authorization attesting that the drug is prescribed to reduce excess body weight and maintain weight reduction, alongside current and ongoing lifestyle modification (structured nutrition and physical activity), and that the patient is at least 18 and meets one of these thresholds at the time GLP-1 therapy began:

• BMI of 35 or higher, or
• BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension (above 140/90 despite two blood pressure medications), or chronic kidney disease stage 3a or above, or
• BMI of 27 or higher with prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

Because the test applies at initiation, someone who started therapy in 2024 at a BMI of 37 and has since come down to 34 can still qualify, as CMS’s own worked example shows.

Who goes through regular Part D instead

Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic MASH are already Part D-covered indications. People with those diagnoses get GLP-1s through their Part D plan and are not eligible for the Bridge, even if they meet its criteria.

Which medications it covers

As of CMS’s latest update, eligible products for weight management are Wegovy (semaglutide, injection and tablets), Zepbound (tirzepatide, KwikPen formulation only), and Foundayo. CMS notes the product list may change during the demonstration. Compounded preparations are not part of the Bridge.

What the $50 copay does and doesn’t include

Eligible beneficiaries pay a $50 copay. Because the drugs sit outside the Part D payment flow, three things follow:

• The Part D deductible does not apply.
• The copay does not count toward the beneficiary’s true out-of-pocket (TrOOP) costs.
• The Low-Income Subsidy does not reduce it.

How the process works

1. The prescriber sends the prescription to a pharmacy.
2. The pharmacy submits the claim to the Bridge and, if prior authorization is needed, sends the request to the prescriber, typically within 24 to 72 hours.
3. The prescriber completes the attestation. The decision goes to the patient and prescriber within 72 hours.
4. There is no formal appeals process. A prescriber can resubmit with corrected or additional information.

Patients can check eligibility at Medicare.gov/glp1bridge or by calling 1-800-MEDICARE.

What it means for employers and benefits teams

Most of the national conversation about GLP-1 coverage this fall is about active employees, and many employers are narrowing or dropping weight-loss coverage for 2027. The Bridge touches a different population:

• Retiree drug coverage. If you sponsor an EGWP, your Medicare-eligible retirees can access the Bridge, and because it runs outside the Part D payment flow, those claims do not land on the plan. That is worth confirming with your PBM and consultant.
• Employees over 65. Working employees who kept employer coverage and never enrolled in Part D are not in the Bridge’s eligible population. Employees weighing a move to Medicare will ask about it, and HR should have a plain answer.
• The clock. The Bridge ends December 31, 2027. Anyone who starts therapy through it will face a coverage question after that date, which is exactly the kind of transition that drives people off treatment.
• The support gap. The Bridge pays for the drug. The attestation requires ongoing nutrition and activity changes, but the demonstration doesn’t fund the coaching and follow-up that keep people on therapy. Persistence is where GLP-1 spending usually leaks, whoever pays for the prescription.

Where Soothe IV fits, and where it doesn’t

Our physician-supervised metabolic program is a cash-pay telehealth program. It is not part of the Medicare GLP-1 Bridge and does not bill Medicare. If you are enrolled in Part D and meet the criteria above, ask your prescriber about the Bridge first; for many people it will be the most affordable route. We would rather you hear that from us than find out later.

Sources

1. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge: overview and FAQs. www.cms.gov
2. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge: information for providers (eligibility, clinical criteria, covered products, process). www.cms.gov
3. Medicare.gov. Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month (beneficiary publication 12234). www.medicare.gov